Cara Therapeutics, Inc.

Informe acción NasdaqCM:CARA

Capitalización de mercado: US$24.3m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Cara Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Cara Therapeutics es Chris Posner , nombrado en Nov 2021, tiene una permanencia de 3.42 años. compensación anual total es $1.07M, compuesta por 68.3% salario y 31.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.24% de las acciones de la empresa, por valor de $57.94K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 5.8 años, respectivamente.

Información clave

Chris Posner

Chief Executive Officer (CEO)

US$1.1m

Compensación total

Porcentaje del salario del CEO68.30%
Permanencia del CEO3.4yrs
Participación del CEO0.2%
Permanencia media de la dirección3.4yrs
Promedio de permanencia en la Junta Directiva5.8yrs

Actualizaciones recientes de la dirección

Artículo de análisis • May 29

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Key Insights Cara Therapeutics to hold its Annual General Meeting on 4th of June CEO Chris Posner's total compensation...

Recent updates

Artículo de análisis • Nov 01

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Cara Therapeutics, Inc.'s ( NASDAQ:CARA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right...
Artículo de análisis • Jul 18

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Cara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders are no doubt pleased to see that the share price has bounced 34...
Artículo de análisis • May 29

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Key Insights Cara Therapeutics to hold its Annual General Meeting on 4th of June CEO Chris Posner's total compensation...
Artículo de análisis • May 25

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

You may think that with a price-to-sales (or "P/S") ratio of 2.2x Cara Therapeutics, Inc. ( NASDAQ:CARA ) is a stock...
Artículo de análisis • Feb 16

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Dec 19

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

To the annoyance of some shareholders, Cara Therapeutics, Inc. ( NASDAQ:CARA ) shares are down a considerable 43% in...
Artículo de análisis • Nov 04

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Celebrations may be in order for Cara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders, with the analysts delivering a...
Artículo de análisis • Oct 25

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Jul 20

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Jun 04

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Unfortunately for some shareholders, the Cara Therapeutics, Inc. ( NASDAQ:CARA ) share price has dived 30% in the last...
Artículo de análisis • Mar 11

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

The latest analyst coverage could presage a bad day for Cara Therapeutics, Inc. ( NASDAQ:CARA ), with the analysts...
Artículo de análisis • Feb 15

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

The analysts covering Cara Therapeutics, Inc. ( NASDAQ:CARA ) delivered a dose of negativity to shareholders today, by...
Artículo de análisis • Feb 06

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Oct 18

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 28

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Cara Therapeutics (NASDAQ:CARA) said its licensing partner Maruishi Pharmaceutical submitted a new drug application (NDA) in Japan for approval of Korsuva (difelikefalin) to treat (itching) pruritus in hemodialysis patients. The NDA is backed by data from a phase 3 trial in Japan, the company said in a Sept. 28 press release. Cara's markets Korsuva in the U.S. with CSL Vifor. The drug is also approved in the U.K., EU and Switzerland, under the name Kapruvia, where Cara's partner is Vifor Fresenius Medical Care Renal Pharma. Vifor Fresenius is a joint company of CSL (OTCPK:CSLLY) (OTCPK:CMXHF) and Fresenius Medical Care (FMS).
Seeking Alpha • Sep 12

Cara Therapeutics hires new finance chief

Cara Therapeutics (NASDAQ:CARA) has appointed Ryan Maynard as its new CFO, effective Sep 12, 2022, the biopharmaceutical company announced in a regulatory filing on Monday. Maynard holds over 20 years of experience in leading finance organizations at both public and private biopharmaceutical companies. He previously served as CFO at global healthcare solutions company, LetsGetChecked. At Cara (CARA), Maynard will serve as the company's principal financial officer and principal accounting officer.
Seeking Alpha • Sep 01

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Summary Korsuva has been approved in an indication for which, it faces little in the way of competition. A number of expansion opportunities await oral difelikefalin, with positive phase 2 data for NP opening the door to additional indications. Language surrounding launch metrics and sales for Q3 sounds cautious, and a near-term disappointment could weigh on share price. Steady history of insider sales and lack of specialist biotech funds holding positions here are possible negative indicators. CARA is a Buy, but only suitable for long-term investors. Key risks include disappointing data for ongoing studies (especially placebo effect) and competition in certain indications (atopic dermatitis). Shares of Cara Therapeutics (CARA) are down 20% over the past 5 years. So far in 2022, they are 15% in the red. I'm always on the lookout for commercial-stage ideas, especially new product launches as that potent combination of accelerating sales momentum and pipeline progress can be hard to resist. Cara caught my eye given the Korsuva launch is underway for an indication (CKD-aP in HD) in which it is the first and only product approved, in addition to bullish remarks from management in the Q2 report where they state "we anticipate demand to accelerate in the coming months, driven by large dialysis organizations that started purchasing early in the third quarter." From what I understand, the positive KOMFORT phase 2 readout in notalgia paresthetica could serve as POC and open the door to multiple other disease categories in both the neurological and dermatology space. Let's take a closer look to determine if Cara fits our criteria for the Core Biotech portfolio and whether there's sufficient commercial and clinical momentum to merit gaining exposure here. Chart FinViz Figure 1: CARA weekly chart When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see a share price spike to the $30 level in Q2 2021 when the FDA and EMA accepted regulatory applications for difelikefalin injection (Korsuva) for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients. From there, the market certainly "taketh away" as the stock plunged on a setback in a mid-stage study in atopic dermatitis. In summer 2022, the share price bottomed around in the $8 level and has slightly rebounded to $10. Overall, I think we are looking at a depressed chart and valuation, so long term investors who believe better days are coming would do well to accumulate a position in the current range. Overview Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational runway for roughly 2 years (I imagine they will access funds via financing by mid 2023 or so). Management's presentation at Canaccord Genuity Growth Conference provides an excellent overview: CEO Christopher Posner and CMO Joana Goncalvez are present, with Posner noting that the company is focused on pruritus (itching) and has an approved therapy Korsuva injection (approved last August). They launched in April this year with partner Vifor Pharma (recently acquired by CSL) with favorable economics in terms of launch. They also have a pipeline-in-a-drug approach with oral difelikefalin and two phase 3 programs initiated this quarter or Q1 (atopic dermatitis and chronic kidney disease in patients pre-dialysis). Third priority is around expanding utilization of oral difelikefalin via two phase 2 programs (recent positive topline data for notalgia paresthetica or NP, and a small phase 2 POC study in primary biliary cholangitis with data readout 2H 22). They have a very strong balance sheet, $204M and guidance to 1H 24 (does not include revenue received from launch). Corporate Slides Figure 2: Combined patient opportunity across lead indications Q2 was the first quarter of launch, total net sales were $17M of which Cara's profit share was $8M. That was comprised mainly of channel stocking (launch inventory in anticipation of future demand). Initial demand is driven by smaller dialysis organizations and recently they got formulary coverage of two largest dialysis organizations (comprise 80% of the market). Recently they announced that the Fresenius Medical Care salesforce is joining the promotional mix as well. They expect demand to steadily increase over the next couple quarters and Q3 will draw down some of that inventory they put in the channel (sounds conservative). Total addressable patient population is 200,000 and most of those preside with Fresenius and DaVita for whom they have formulary coverage. They are fully reimbursed by Medicare for minimum of 2 years (granted in April) via TDAPA designation (only other analogue is Amgen's parsabiv launched in 2018 and they had TDAPA designation for 3 years). Once they get out of the TDAPA payment, the product goes into the bundle and they would expect it to increase to cover an innovative drug like Korsuva. One distinction though is that parsabiv went into the bundle with two other drugs including generic oral version that shifted incentive to generic, whereas Korsuva would go into the bundle with additional funding without any additional competition as there are no competitors in that functional category). CMS recently came out with proposed rule for 2023 for end stage renal disease patients in the bundle/payment system, and they specifically call out concerns for drugs designated with TDAPA (proposed four options that all are positive in terms of adding additional money outside the bundle for an innovative drug like Korsuva). We probably won't hear back from them on this issue until 2024. Early days of launched, shipped 1800 vials to dialysis clinics and anecdotally feedback is quite positive (very high levels of awareness among nephrologists and very high intent to treat). Week over week they are seeing increases in number of clinics ordering and majority of them reordering (gives hope that they are having positive first experiences with the product). Moving on to oral Korsuva, NP indication is an interesting opportunity and affects 650,000 patients. It's treated by medical dermatologists and there are no FDA-approved therapies for this neuropathic itch. The strategy is to look at their drug in systemic, dermatologic and neuropathic conditions to demonstrate broad utility. Data showed that the drug works broadly across disease areas regardless of the underlying pathogenesis (what's causing that itch). It also confirmed the mechanism of action, works with strong neuro-modulatory manner to inhibit the itch. Corporate Slides Figure 3: Positive POC data in NP shows path forward to broader utility NP is a more homogenous type of itch and patient (itch is just neuropathic and strong data is a result of strong neuro-modulatory effect). Atopic dermatitis itch is a combination of inflammatory component as well as neuro-modulatory, so oral difelikefalin should work there. The company's phase 3 program is using it as an adjunct to topical corticosteroids (address inflammatory itch) while difelikefalin addresses the neuro-modulatory. In systemic itch, pathogenesis is multi-factorial and drug should work there given prior data. Placebo response does vary by condition. NP is the first study (nothing else is in trials) and going forward data has been submitted to dermatological conference (placebo response could go higher in the future). 4 point response was the primary endpoint and was around 20%. In Atopic dermatitis they saw 20% placebo effect in mild-to-moderate patient population as well. Stage 3 patients (higher placebo response) have not been included in the ongoing phase 3 study. On the con side, pain and itch are very subjective endpoints. Corporate Slides Figure 4: Phase 2 data in AD focusing on mild-to-moderate subgroup For atopic dermatitis, management acknowledges the evolving competitive landscape and flurry of development in the moderate to severe space and it's all focused on inflammatory component coupled with disease modification. Topicals are still utilized in mild to moderate cases and they are not always effective. Placebo effect to my eyes is the big risk for phase 3 study especially considering the prior phase 2 trial failed to meet the primary endpoint in the moderate to severe population and the company chose to instead focus on the key secondary endpoint (percentage of patients who achieved an improvement from a baseline of ≥4 points in the weekly mean of the daily 24-hour Itch NRS score at week 12, which is now the registration endpoint). They are confident about design being optimal, but reading between the lines I think the CEO sounded less confident on actually achieving the primary endpoint. Majority of these patients they are enrolling are mild to moderate. Safety profile repeatedly shows consistency and predictability. Across different disease areas they see predominantly GI effects, headache and dizziness. With long term use they do not expect it to look any different (events did not increase over time, some decrease over time as they typically occur in first few weeks on treatment). As for phase 2 in PBC, this is a small proof of concept study (just want to see numerical separation and positive signal). They want to see consistent pattern of effect, early onset of action and sustained effect. For the IV product, they are fully-partnered with Vifor in the US and EU (who owns nearly 14% of the company, not a stretch to think they decide to simply buy Cara out at some point). For wholly-owned oral difelikefalin, they will look for ex US partnerships and in the US retain the option to 'go it solo' in commercializing (especially for concentrated markets). Other Information For the second quarter of 2022, the company reported cash and equivalents of $204M as compared to $30M cash used in operating activities. Net loss was $4.2M, while total revenues amounted to $23M ($15M milestone payment for Kapruvia approval and $8M in collaboration revenue related to profit-sharing). Research and development expenses fell to $19.9M, while G&A rose to $7.6M. Again, management is guiding for operational runway into 1H 2024 (this is conservative, as they are not including any product revenue received or milestone payments that could come). Accumulated deficit is $480M and again I would expect another financing at some point in 2023, perhaps the back half of the year. On the conference call, regarding launch metrics and what to expect in the future, management reminds us that for them to record revenue Vifor must ship to wholesalers and then demand is generated (sounds again like Q3 could be soft or below expectations before the ensuing uptick). The CEO expects demand to accelerate into the back half of the year as Fresenius and Davita are online, formulary protocols are in place and they are starting to see ordering done by clinics. Again, keep in mind that the $8M in revenue received on net sales of just under $17M amounts to 47% of net sales (assumes 60% profit split at non-Fresenius accounts). As for prior financings, the July 2019 secondary offering took place at price point of $23/share (representing a double from current levels). Moving on to nuggets from other presentations, the KOMFORT readout call was certainly worth listening to: The big idea here with oral difelikefalin (DFK) is to provide clinical benefit regardless of underlying cause of pruritus, to treat it across a broad variety of disease categories. NP data affirms core strategy is on target and on track. As for market opportunity in NP, they estimate 2.7M adults have neuropathic itch including NP (disease significantly underdiagnosed with only a quarter of NP patients under care of a provider). There are no FDA approved therapies and off label treatments currently used have little or no efficacy or safety & tolerability concerns. In addition to data mentioned in Figure 3, significantly greater proportion of patients on DFK achieved 4 point improvement in WI-NRS compared to placebo (endpoint regulators will be looking at in pivotal studies). 41% of patients on DFK versus 18% on placebo with statistical separation versus placebo seen as early as week 2 and sustained through week 8. Corporate presentation Figure 5: Promising efficacy in NP on registrational endpoint As for safety data, there were similar proportion of patients reporting 1 treatment related adverse event on DFK and placebo. Most events were mild to moderate in severity, with one severe event occurring on placebo. 12 patients on DFK (19.4%) and 4 on placebo (6.3%) discontinued due to adverse event (concerningly high number on DFK arm). Dizziness and nausea were most common events. In Q&A, as for rates of discontinuation, management states that discontinuation rate in NP was consistent with what they saw in atopic dermatitis. They will need to do some "dose finding" going forward, but are not considering titration. As for institutional investors of note, I mentioned prior that Vifor owns nearly 14% of the company. Otherwise, a possible red flag or at least neutral point is that I see mainly generalist funds in this one (BlackRock with 13.5% stake and Vanguard with 5.6% stake). As for insiders, CEO Chris Posner owns over 200,00 shares. Steady history of sales by multiple members of leadership over the past year(s) is not encouraging.
Seeking Alpha • Aug 19

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

The Swiss Agency for Therapeutic Products (Swissmedic) approved Cara Therapeutics (NASDAQ:CARA) and Vifor Fresenius Medical Care Renal Pharma's Kapruvia (difelikefalin) to treat moderate-to-severe pruritus (itching) associated with chronic kidney disease in adult hemodialysis patients. The companies said Kapruvia is the first and only therapy approved through consortium filing for treating this particular condition in these patients. The approval was backed by data from two pivotal phase 3 trials – KALM-1, conducted in the U.S., and the global study, dubbed KALM-2 — plus supportive data from an additional 32 clinical studies. Kapruvia is approved in Canada under the name Korsuva. The companies expect regulatory decisions in Australia and Singapore by the end of 2022. Vifor Fresenius is a joint company of CSL (OTCPK:CSLLY) (OTCPK:CMXHF) and Fresenius Medical Care (FMS). CSL had acquired Vifor Pharma (OTCPK:GNHAY) in a ~$11.7B deal.
Seeking Alpha • Aug 08

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Cara Therapeutics press release (NASDAQ:CARA): Q2 GAAP EPS of -$0.08 beats by $0.18. Revenue of $23M beats by $1.97M. Cash, cash equivalents and marketable securities at June 30, 2022 totaled $204.7 million compared to $236.8 million at December 31, 2021. The decrease in the balance primarily resulted from $30.0 million of cash used in operating activities. Shares -6.43%.
Seeking Alpha • Jun 24

Calls A Much Safer Way To Buy Cara Therapeutics

Since I wrote my bullish call on Cara Therapeutics, the shares have absolutely collapsed. I thought I'd revisit the name again to see if I should add, hold, or sell. The company reported earnings, and the same trend persists: the company sells more, and loses more, and this trend needs to be reversed. I think call options are the best way to play this. They give most of the upside, at a fraction of the cost.
Artículo de análisis • Jun 15

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • May 12

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

Cara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 21

Taking A (Speculative) Position In Cara Therapeutics

I think the financial history here has been pretty bad. The company has only turned a profit in one of the past nine years. That said, investors in companies like this care far less about the past than the future, and the shares are reasonably priced in my view. Since this is a bit of a lottery ticket, most of my bullishness will be expressed via call options. These offer most of the taste at far less calories.
Artículo de análisis • Mar 09

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Posner en comparación con los beneficios de Cara Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2024US$1mUS$728k

-US$71m

Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$123m

Dec 31 2023US$3mUS$728k

-US$119m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$112m

Mar 31 2023n/an/a

-US$84m

Dec 31 2022US$3mUS$700k

-US$85m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$93m

Dec 31 2021US$10mUS$116k

-US$88m

Sep 30 2021n/an/a

US$24m

Jun 30 2021n/an/a

US$8m

Mar 31 2021n/an/a

US$14m

Dec 31 2020US$280kn/a

US$8m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$115m

Mar 31 2020n/an/a

-US$113m

Dec 31 2019US$302kn/a

-US$106m

Sep 30 2019n/an/a

-US$98m

Jun 30 2019n/an/a

-US$85m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$494kn/a

-US$74m

Compensación vs. Mercado: La compensación total de Chris($USD1.07M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD638.05K).

Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.

CEO

Chris Posner (53 yo)

3.4yrs
Permanencia
US$1,065,879
Compensación

Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Posner
President3.4yrsUS$1.07m0.24%
$ 57.9k
Ryan Maynard
Chief Financial Officer2.6yrsUS$607.28k0.015%
$ 3.5k
Scott Terrillion
Chief Compliance Officer8.4yrsUS$592.86k0.16%
$ 38.3k
Matthew Murphy
Manager of Investor Relationsno datasin datossin datos
3.4yrs
Permanencia media
55yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de CARA se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Posner
President6.7yrsUS$1.07m0.24%
$ 57.9k
Martin Vogelbaum
Independent Chairman & Lead Independent Director14.8yrsUS$520.00k0.20%
$ 48.6k
Graeme Milligan
Member of the Scientific Advisory Boardno datasin datossin datos
Stanley Watson
Member of the Scientific Advisory Boardno datasin datossin datos
James Kauer
Member of the Scientific Advisory Boardno datasin datossin datos
Philip Portoghese
Member of the Scientific Advisory Boardno datasin datossin datos
Jeffrey L. Ives
Independent Director10.8yrsUS$272.50k0.087%
$ 21.2k
Helen Boudreau
Independent Director1.7yrsUS$270.00k0%
$ 0
Susan Shiff
Independent Director4.8yrsUS$262.50k0.094%
$ 22.8k
Lisa von Moltke
Independent Director2.4yrsUS$255.00k0.059%
$ 14.3k
5.8yrs
Permanencia media
61.5yo
Promedio de edad

Junta con experiencia: La junta directiva de CARA se considera experimentada (5.8 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2025/04/16 17:23
Precio de las acciones al final del día2025/04/15 00:00
Beneficios2024/12/31
Ingresos anuales2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Cara Therapeutics, Inc. está cubierta por 12 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Jason Matthew GerberryBofA Global Research
Kenneth TrbovichBrean Capital Historical (Janney Montgomery)
Corey DavisCanaccord Genuity